RhoGDIα downregulates androgen receptor signaling in prostate cancer cells

Prostate

Volumn 73, Issue 15, 2013, Pages 1614-1622

  Zhu, Yezi ^a,b   Liu, Chengfei ^a   Tummala, Ramakumar ^a   Nadiminty, Nagalakshmi ^a   Lou, Wei ^a   Gao, Allen C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AR; prostate cancer; RhoGDI

Indexed keywords

ANDROGEN RECEPTOR; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR 1;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AR; PROSTATE CANCER; RHOGDIΑ;

CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR ALPHA; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84884901582     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22615     Document Type: Article

References (54)

1. Harris WP, Mostaghel EA, Nelson PS, Montgomery B,. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6 (2): 76-85.
2. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN,. Castration-resistant prostate cancer: Current and emerging treatment strategies. Drugs 2010; 70 (8): 983-1000.
3. Kim SJ, Kim SI,. Current treatment strategies for castration-resistant prostate cancer. Korean J Urol 2011; 52 (3): 157-165.
4. Trapman J, Cleutjens KB,. Androgen-regulated gene expression in prostate cancer. Semin Cancer Biol 1997; 8 (1): 29-36.
5. Kung HJ, Evans CP,. Oncogenic activation of androgen receptor. Urol Oncol 2009; 27 (1): 48-52.
6. Olofsson B,. Rho guanine dissociation inhibitors: Pivotal molecules in cellular signalling. Cell Signal 1999; 11 (8): 545-554.
7. Dovas A, Couchman JR,. RhoGDI: Multiple functions in the regulation of Rho family GTPase activities. Biochem J 2005; 390 (Pt 1): 1-9.
8. Johnson JL, Erickson JW, Cerione RA,. New insights into how the Rho guanine nucleotide dissociation inhibitor regulates the interaction of Cdc42 with membranes. J Biol Chem 2009; 284 (35): 23860-23871.
9. Takaishi K, Kikuchi A, Kuroda S, Kotani K, Sasaki T, Takai Y,. Involvement of rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI) in cell motility. Mol Cell Biol 1993; 13 (1): 72-79.
10. Zhang B,. Rho GDP dissociation inhibitors as potential targets for anticancer treatment. Drug Resist Update 2006; 9 (3): 134-141.
11. Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Ando S, Fuqua SA,. Loss of Rho GDIalpha and resistance to tamoxifen via effects on estrogen receptor alpha. J Natl Cancer Inst 2011; 103 (7): 538-552.
12. Togawa A, Miyoshi J, Ishizaki H, Tanaka M, Takakura A, Nishioka H, Yoshida H, Doi T, Mizoguchi A, Matsuura N, Niho Y, Nishimune Y, Nishikawa S, Takai Y,. Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha. Oncogene 1999; 18 (39): 5373-5380.
13. Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D,. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis 2000; 18 (6): 519-525.
14. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K, Mansel RE,. Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 2003; 9 (17): 6432-6440.
15. Zhu Y, Tummala R, Liu C, Nadiminty N, Lou W, Evans CP, Zhou Q, Gao AC,. RhoGDIalpha suppresses growth and survival of prostate cancer cells. Prostate 2012; 72 (4): 392-398.
16. Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, Evans CP, Zhou Q, Gao AC,. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 2010; 70 (8): 3309-3319.
17. Lee SO, Lou W, Hou M, Onate SA, Gao AC,. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 2003; 22 (39): 7981-7988.
18. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocr Rev 2004; 25 (2): 276-308.
19. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J,. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69 (1): 16-22.
20. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y,. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69 (6): 2305-2313.
21. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ,. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68 (13): 5469-5477.
22. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T,. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61 (9): 3550-3555.
23. Tilley WD, Buchanan G, Hickey TE, Bentel JM,. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996; 2 (2): 277-285.
24. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ,. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006; 91 (10): 3850-3856.
25. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS,. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007; 67 (10): 5033-5041.
26. Mostaghel EA, Nelson PS,. Intracrine androgen metabolism in prostate cancer progression: Mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 2008; 22 (2): 243-258.
27. Marks LS, Mostaghel EA, Nelson PS,. Prostate tissue androgens: History and current clinical relevance. Urology 2008; 72 (2): 247-254.
28. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS,. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008; 68 (11): 4447-4454.
29. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66 (5): 2815-2825.
30. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS,. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10 (2): 440-448.
31. Visakorpi T,. New pieces to the prostate cancer puzzle. Nat Med 1999; 5 (3): 264-265.
32. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C,. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999; 96 (10): 5458-5463.
33. Chen T, Wang LH, Farrar WL,. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 2000; 60 (8): 2132-2135.
34. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC,. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003; 9 (1): 370-376.
35. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z,. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998; 58 (20): 4640-4645.
36. Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL,. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol Endocrinol 2008; 22 (3): 597-608.
37. Frigo DE, Sherk AB, Wittmann BM, Norris JD, Wang Q, Joseph JD, Toner AP, Brown M, McDonnell DP,. Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. Mol Endocrinol 2009; 23 (9): 1385-1396.
38. Agoulnik IU, Bingman WE III, Nakka M, Li W, Wang Q, Liu XS, Brown M, Weigel NL,. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol 2008; 22 (11): 2420-2432.
39. Kazmin D, Prytkova T, Cook CE, Wolfinger R, Chu TM, Beratan D, Norris JD, Chang CY, McDonnell DP,. Linking ligand-induced alterations in androgen receptor structure to differential gene expression: A first step in the rational design of selective androgen receptor modulators. Mol Endocrinol 2006; 20 (6): 1201-1217.
40. Yeh S, Miyamoto H, Shima H, Chang C,. From estrogen to androgen receptor: A new pathway for sex hormones in prostate. Proc Natl Acad Sci USA 1998; 95 (10): 5527-5532.
41. Rao S, Lyons LS, Fahrenholtz CD, Wu F, Farooq A, Balkan W, Burnstein KL,. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene 2012; 31: 716-727.
42. Agoulnik IU, Weigel NL,. Coactivator selective regulation of androgen receptor activity. Steroids 2009; 74 (8): 669-674.
43. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM,. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448 (7153): 595-599.
44. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310 (5748): 644-648.
45. Shi XB, Tepper CG, de Vere White RW,. MicroRNAs and prostate cancer. J Cell Mol Med 2008; 12 (5A): 1456-1465.
46. Sun T, Yang M, Kantoff P, Lee GS,. Role of microRNA-221/-222 in cancer development and progression. Cell Cycle 2009; 8 (15): 2315-2316.
47. El Marzouk S, Schultz-Norton JR, Likhite VS, McLeod IX, Yates JR, Nardulli AM,. Rho GDP dissociation inhibitor alpha interacts with estrogen receptor alpha and influences estrogen responsiveness. J Mol Endocrinol 2007; 39 (4): 249-259.
48. Su LF, Wang Z, Garabedian MJ,. Regulation of GRIP1 and CBP Coactivator activity by Rho GDI modulates estrogen receptor transcriptional enhancement. J Biol Chem 2002; 277 (40): 37037-37044.
49. Garcia-Mata R, Boulter E, Burridge K,. The 'invisible hand': Regulation of RHO GTPases by RHOGDIs. Nat Rev Mol Cell Biol 2011; 12 (8): 493-504.
50. Lyons LS, Burnstein KL,. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol 2006; 20 (5): 1061-1072.
51. Peacock SO, Fahrenholtz CD, Burnstein KL,. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Mol Endocrinol 2012; [Epub ahead of print].
52. Metzger E, Muller JM, Ferrari S, Buettner R, Schule R,. A novel inducible transactivation domain in the androgen receptor: Implications for PRK in prostate cancer. EMBO J 2003; 22 (2): 270-280.
53. Schmidt LJ, Duncan K, Yadav N, Regan KM, Verone AR, Lohse CM, Pop EA, Attwood K, Wilding G, Mohler JL, Sebo TJ, Tindall DJ, Heemers HV,. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol Endocrinol 2012; 26 (5): 716-735.
54. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ,. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003; 63 (8): 1981-1989.